The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

"And we're not used to having somebody without a career at stake in the room at a senior level," said Hudson.

Paul Hudson, CEO of Sanofi, said the pharmaceutical company ... The pharmaceutical company, which makes drugs like Lantus insulin jabs and Plavix blood thinners, spends about three billion euros ...

Sanofi's CEO said the pharma firm uses AI to ... The pharmaceutical company, which makes drugs like Lantus insulin jabs and Plavix blood thinners, spends about three billion euros, or $3.1 billion ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Sanofi is looking at ways to revive its flagging diabetes business, and yesterday revealed some of the new ideas it has up its sleeve. The company’s biggest seller is basal insulin Lantus ...

It sells products through independent distributors primarily in India.Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India.

It has its own manufacturing facility at Goa. It sells products through independent distributors primarily in India.Sanofi India's products viz. Lantus Combiflam Amaryl and Allegra feature in the top ...